Int J Stem Cells.  2023 Nov;16(4):415-424. 10.15283/ijsc23062.

Preclinical Study on Biodistribution of Mesenchymal Stem Cells after Local Transplantation into the Brain

• Bashyal N
• Kim MG
• Jung JH
• Acharya R
• Lee YJ
• Hwang WS
• Choi JM
• Chang DY
• Kim SS
• Suh-Kim H

• KMID: 2548005
• DOI: http://doi.org/10.15283/ijsc23062

Abstract

Therapeutic efficacy of mesenchymal stem cells (MSCs) is determined by biodistribution and engraftment in vivo. Compared to intravenous infusion, biodistribution of locally transplanted MSCs are partially understood. Here, we performed a pharmacokinetics (PK) study of MSCs after local transplantation. We grafted human MSCs into the brains of immune-compromised nude mice. Then we extracted genomic DNA from brains, lungs, and livers after transplantation over a month. Using quantitative polymerase chain reaction with human Alu-specific primers, we analyzed biodistribution of the transplanted cells. To evaluate the role of residual immune response in the brain, MSCs expressing a cytosine deaminase (MSCs/CD) were used to ablate resident immune cells at the injection site. The majority of the Alu signals mostly remained at the injection site and decreased over a week, finally becoming undetectable after one month. Negligible signals were transiently detected in the lung and liver during the first week. Suppression of Iba1-positive microglia in the vicinity of the injection site using MSCs/CD prolonged the presence of the Alu signals. After local transplantation in xenograft animal models, human MSCs remain predominantly near the injection site for limited time without disseminating to other organs. Transplantation of human MSCs can locally elicit an immune response in immune compromised animals, and suppressing resident immune cells can prolong the presence of transplanted cells. Our study provides valuable insights into the in vivo fate of locally transplanted stem cells and a local delivery is effective to achieve desired dosages for neurological diseases.

Keyword

Mesenchymal stem cell; Pharmacokinetics; Real-time polymerase chain reaction; Immune response; Brain; Transplantation

Figure

• 

  Fig. 1 Quantification of human cells by Alu J specific polymerase chain reaction (PCR) of genomic DNA (gDNA). (A) Schematic representation showing the method to prepare the human gene standard and human Alu J specific quantitative PCR (qPCR). gDNA from human mesenchymal stem cells (MSCs) were mixed with mouse brain gDNA to prepare standard DNA for qPCR. (B) Standard cu-rve generated from standard DNAs’ cycle threshold (Ct) values. (C) Con-centration of standard DNA used for Alu J qPCR and their respective Ct values obtained from qPCR. Data are mean±SD of three independent experiments. LLOQ: lower limit of quantification.

• 

  Fig. 2 Pharmacokinetics study of human mesenchymal stem cells (MSCs) transplanted into nude mice brain. (A) Schematic representation showing injection of MSCs in nude mouse striatum and genomic DNA (gDNA) preparation from brain, lungs, and liver on day 0, 1, 3, 8, and 28 after cell transplantation. (B) Quantification of human gene in ipsilateral brain (ipsi - brain), liver, lungs, and contralateral brain (contra - brain) from gDNA at indicated days by Alu J specific quantitative polymerase chain reaction (qPCR). Total number of animals per group is indicated just above bar graph in ipsi - brain. Low limit of quantification (LLOQ) is indicated by dotted lines. Values above bar graph in liver, lungs, contra - brain indicate relative rate of human gene in these organs compared to ipsi - brain at day 0. Data are mean± SEM of at least 10 animals per group. **p<0.01, ***p<0.001, compared to day 0, ipsi - brain group; one-way ANOVA test.

• 

  Fig. 3 Generation and characterization of mesenchymal stem cells expressing a cytosine deaminase (MSCs/CD), and effect of in vivo ablation of neighboring cells on the cell fate of transplanted MSCs/CD in the brain. (A) Schematic diagram of 5-fluorocytosine (5-FC) induced suicidal effect and bystander effect in MSCs/CD. (B) Mesodermal differentiation of MSCs and MScs/CD. Adipogenic differentiation showing Oil Red positive lipid droplets in bright field images of MSCs and MSCs/CD (B1, B2). Osteogenic differentiation showing alizarin red S stained precipitates in bright field images of MSCs and MSCs/CD (B3, B4). Chondrogenic differentiation of MSCs and MSCs/CD showing Alcian blue positive chondrocytes in bright field image (B5, B6). Scale bar=200 μm. (C) FACS analysis showing the surface antigen expression in MSCs and MSCs/CD. Isotype controls were used to determine the backgrounds. Black dotted peaks indicate the results obtained from cells stained with isotype control antibodies and red peaks indicate the results of cells stained with the indicated specific target antibodies. (D) Summary of FACS analysis showing the similar phenotype of MSCs and MSCs/CD: positive for CD29, CD90, and CD105 and negative for CD34, CD45, and HLA-DR. Data are mean±SEM from 3 independent experiments. (E) Experimental plan for 5-FC treatment to mice after MSCs/CD transplantation. (F) Representative immunofluorescence images show the detection of human mitochondrial-positive cells (α-hMT) with and without 5-FC administration. Scale bar=50 μm. (G) Comparison of relative rates of human cells detected at day 0 (d0) and day 8 (d8) with or without 5-FC administration. Data are mean±SEM of at least 10 animals per group. ###p<0.001, compared to d0 without 5-FC administered group; ***p<0.001, compared to d8 without 5-FC administered group; Student’s t-test.

• 

  Fig. 4 In vivo ablation of injected and neighboring cells with cytosine deaminase (CD) and 5-fluorocytosine (5-FC) prolongs the transplanted cells at the injection site. (A) Experimental plan for 5-FC administration (1,000 mg/kg/day) to nude mice brain after mesenchymal stem cells expressing a CD (MSCs/CD) (3×105 cells) transplantation. Animal were sacrifice and genomic DNA (gDNA) extracted from injected brain at day 0 (d0), d1, d3, d8, d14, and d28 after cell transplantation. The 5-FC non administered group was used as a control. (B) Data are mean±SEM of at least 5 animals per group. *p<0.05, **p<0.01, ***p<0.001, compared to data without 5-FC administered group; Student’s t-test. Comparison of human cells detected by quantitative polymerase chain reaction in the ipsilateral brain at d0, d1, d3, d8, d14, and d28 with or without 5-FC administration. (C) Representative immunohistochemical images with anti-human mitochondrial antigen (hMT) showing the human cells at the injection site of the animals. Scale bar=100 μm.

• 

  Fig. 5 In vivo ablation of injected and neighboring cells with cytosine deaminase (CD) and 5-fluorocytosine (5-FC) differentially modulates immune response at the injection site. (A) Serially sectioned brains were stained for cell death at the injection site with Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL, red). The sections were counter-stained with Hoechst 33258 to show the nuclei (blue). The TUNEL-positive cells were detected at the injection site at day 1 (d1) in the control group, whereas they were dramatically increased at day 3∼8 (d3∼d8) in the 5-FC treated animal. (B) Serial sections were stained with an anti-Iba1 antibody to identify activated microglia at the injection site. Note dramatic increases of Iba-1 positive microglia only in the control group but not in the 5-FC treated group. Scale bar=100 μm. A minimum of two animals per group were utilized in our study. The representative one is shown.

Reference

References

1. Gnecchi M, Danieli P, Malpasso G, Ciuffreda MC. 2016; Para-crine mechanisms of mesenchymal stem cells in tissue repair. Methods Mol Biol. 1416:123–146. DOI: 10.1007/978-1-4939-3584-0_7. PMID: 27236669.

2. Fan XL, Zhang Y, Li X, Fu QL. 2020; Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell Mol Life Sci. 77:2771–2794. DOI: 10.1007/s00018-020-03454-6. PMID: 31965214. PMCID: PMC7223321.

3. Kim N, Cho SG. 2015; New strategies for overcoming limitations of mesenchymal stem cell-based immune modulation. Int J Stem Cells. 8:54–68. DOI: 10.15283/ijsc.2015.8.1.54. PMID: 26019755. PMCID: PMC4445710.

4. Han KH, Kim AK, Kim DI. 2016; Therapeutic potential of human mesenchymal stem cells for treating ischemic limb diseases. Int J Stem Cells. 9:163–168. DOI: 10.15283/ijsc16053. PMID: 27871151. PMCID: PMC5155711.

5. Hosseini SM, Farahmandnia M, Razi Z, et al. 2015; Combination cell therapy with mesenchymal stem cells and neural stem cells for brain stroke in rats. Int J Stem Cells. 8:99–105. DOI: 10.15283/ijsc.2015.8.1.99. PMID: 26019759. PMCID: PMC4445714.

6. Kim GH, Subash M, Yoon JS, et al. 2020; Neurogenin-1 overexpression increases the therapeutic effects of mesenchymal stem cells through enhanced engraftment in an ischemic rat brain. Int J Stem Cells. 13:127–141. DOI: 10.15283/ijsc19111. PMID: 31887850. PMCID: PMC7119213.

7. Kurtz A. 2008; Mesenchymal stem cell delivery routes and fate. Int J Stem Cells. 1:1–7. DOI: 10.15283/ijsc.2008.1.1.1. PMID: 24855503. PMCID: PMC4021770.

8. Dabbagh F, Schroten H, Schwerk C. 2022; In vitro models of the blood-cerebrospinal fluid barrier and their applications in the development and research of (neuro)pharmaceuticals. Pharmaceutics. 14:1729. DOI: 10.3390/pharmaceutics14081729. PMID: 36015358. PMCID: PMC9412499. PMID: 77cb2ccd1dc7453eb1c66cc8732d8fda.

9. Achón Buil B, Tackenberg C, Rust R. 2023; Editing a gateway for cell therapy across the blood-brain barrier. Brain. 146:823–841. DOI: 10.1093/brain/awac393. PMID: 36397727. PMCID: PMC9976985.

10. Wang S, Guo L, Ge J, et al. 2015; Excess integrins cause lung entrapment of mesenchymal stem cells. Stem Cells. 33:3315–3326. DOI: 10.1002/stem.2087. PMID: 26148841.

11. Gholamrezanezhad A, Mirpour S, Bagheri M, et al. 2011; In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. Nucl Med Biol. 38:961–967. DOI: 10.1016/j.nucmedbio.2011.03.008. PMID: 21810549.

12. Turk OM, Woodall RC, Gutova M, Brown CE, Rockne RC, Munson JM. 2021; Delivery strategies for cell-based therapies in the brain: overcoming multiple barriers. Drug Deliv Transl Res. 11:2448–2467. DOI: 10.1007/s13346-021-01079-1. PMID: 34718958. PMCID: PMC8987295.

13. Cha GD, Jung S, Choi SH, Kim DH. 2022; Local drug delivery strategies for glioblastoma treatment. Brain Tumor Res Treat. 10:151–157. DOI: 10.14791/btrt.2022.0017. PMID: 35929112. PMCID: PMC9353160.

14. Chang DY, Yoo SW, Hong Y, et al. 2010; The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. Int J Cancer. 127:1975–1983. DOI: 10.1002/ijc.25383. PMID: 20473873.

15. Chang DY, Jung JH, Kim AA, et al. 2020; Combined effects of mesenchymal stem cells carrying cytosine deaminase gene with 5-fluorocytosine and temozolomide in orthotopic glioma model. Am J Cancer Res. 10:1429–1441. PMID: 32509389. PMCID: PMC7269785.

16. Cavarretta IT, Altanerova V, Matuskova M, Kucerova L, Culig Z, Altaner C. 2010; Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther. 18:223–231. DOI: 10.1038/mt.2009.237. PMID: 19844197. PMCID: PMC2839205.

17. Kim SS, Choi JM, Kim JW, et al. 2005; cAMP induces neuronal differentiation of mesenchymal stem cells via activation of extracellular signal-regulated kinase/MAPK. Neuroreport. 16:1357–1361. DOI: 10.1097/01.wnr.0000175243.12966.f5. PMID: 16056139.

18. Bashyal N, Lee TY, Chang DY, et al. 2022; Improving the safety of mesenchymal stem cell-based ex vivo therapy using herpes simplex virus thymidine kinase. Mol Cells. 45:479–494. DOI: 10.14348/molcells.2022.5015. PMID: 35356894. PMCID: PMC9260133.

19. Park JS, Chang DY, Kim JH, et al. 2013; Retrovirus-mediated transduction of a cytosine deaminase gene preserves the stemness of mesenchymal stem cells. Exp Mol Med. 45:e10. DOI: 10.1038/emm.2013.21. PMID: 23429359. PMCID: PMC3584665.

20. Piovesan A, Pelleri MC, Antonaros F, Strippoli P, Caracausi M, Vitale L. 2019; On the length, weight and GC content of the human genome. BMC Res Notes. 12:106. DOI: 10.1186/s13104-019-4137-z. PMID: 30813969. PMCID: PMC6391780. PMID: 2aed8282179d401db795a5e2d7682b4e.

21. Dominici M, Le Blanc K, Mueller I, et al. 2006; Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position state-ment. Cytotherapy. 8:315–317. DOI: 10.1080/14653240600855905. PMID: 16923606.

22. Kidd S, Spaeth E, Dembinski JL, et al. 2009; Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 27:2614–2623. DOI: 10.1002/stem.187. PMID: 19650040. PMCID: PMC4160730.

23. Doucette T, Rao G, Yang Y, et al. 2011; Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a glioma model. Neoplasia. 13:716–725. DOI: 10.1593/neo.101680. PMID: 21847363. PMCID: PMC3156662. PMID: 9a269fcfc62d4b21b5d423c7fdac2f6d.

24. Portnow J, Synold TW, Badie B, et al. 2017; Neural stem cell-based anticancer gene therapy: a first-in-human study in recurrent high-grade glioma patients. Clin Cancer Res. 23:2951–2960. DOI: 10.1158/1078-0432.CCR-16-1518. PMID: 27979915. PMCID: PMC8843778.

25. Cloughesy TF, Landolfi J, Vogelbaum MA, et al. 2018; Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro Oncol. 20:1383–1392. DOI: 10.1093/neuonc/noy075. PMID: 29762717. PMCID: PMC6120351.

26. Jung JH, Kim AA, Chang DY, Park YR, Suh-Kim H, Kim SS. 2015; Three-dimensional assessment of bystander effects of mesenchymal stem cells carrying a cytosine deaminase gene on glioma cells. Am J Cancer Res. 5:2686–2696. DOI: 10.1093/neuonc/nov209.40. PMID: 26609476. PMCID: PMC4638682.

27. Shimizu K, Iyoda T, Okada M, Yamasaki S, Fujii SI. 2018; Immune suppression and reversal of the suppressive tumor microenvironment. Int Immunol. 30:445–454. DOI: 10.1093/intimm/dxy042. PMID: 29939325.

28. Vincent J, Mignot G, Chalmin F, et al. 2010; 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70:3052–3061. DOI: 10.1158/0008-5472.CAN-09-3690. PMID: 20388795.